Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riliprubart (BIVV020) in Persistent/Chronic ITP
NCT04669600Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- IgG Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of riliprubart in immune thrombocytopenia (ITP), sponsored by Sanofi. Primary endpoint: Percentage of Participants With a Durable Platelet Response. Started Feb 2021; status: completed.
02
Drugs
riliprubart
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04669600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669600.